AZD 4831

Drug Profile

AZD 4831

Alternative Names: AZD4831

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Cardiotonics; Cardiovascular therapies; Small molecules
  • Mechanism of Action Peroxidase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Heart failure

Most Recent Events

  • 22 Nov 2017 AstraZeneca completes a phase-I clinical trials in Heart failure (In volunteers) in USA (PO) (NCT03136991)
  • 15 May 2017 Phase-I clinical trials in Heart failure (In volunteers) in USA (PO) (NCT03136991)
  • 05 May 2017 AstraZeneca plans a phase I trial in Healthy volunteers in USA (NCT03136991)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top